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Background: Angiogenesis is closely related to the growth, invasion and metastasis of tumors, also considered as
the key target of anticancer therapy. Scutellaria barbata D. Don (S. barbata), a traditional Chinese medicine, is being
used to treat various diseases, including cancer. However, the antitumor molecular mechanism of S. barbata was still
unclear. This study aimed to investigate the inhibitory effects of the total flavones in S. barbata (TF-SB) on angiogenesis.
Methods: Human umbilical vein endothelial cells (HUVECs) were treated with various concentrations of TF-SB. Cell
viability was examined using the MTT assay. The scratch assay was used to detect the migration of HUVECs after
treatment with TF-SB. The ability of HUVECs to form network structures in vitro was demonstrated using the tube
formation assay. The chick embryo chorioallantoic membrane assay was performed to detect the in vivo anti-
angiogenic effect. The expression of VEGF was measured by the enzyme-linked immunosorbent.
Results: Results showed that TF-SB inhibited the proliferation and migration of HUVECs in a dose- dependent manner.
Simultaneously, TF-SB significantly suppressed HUVEC angiogenesis in vitro and in vivo. Furthermore, VEGF was
downregulated in both HUVECs and MHCC97-H cells after TF-SB treatment.
Conclusion: TF-SB could suppress the process of angiogenesis in vitro and in vivo. TF-SB potentially suppresses
angiogenesis in HUVECs by regulating VEGF. These findings suggested that TF-SB may serve as a potent anti-
angiogenic agent.
Keywords: Scutellaria Barbata, Angiogenesis, Hepatocellular Carcinoma, Human Umbilical Vein Endothelial CellsBackground
The incidence of hepatocellular carcinoma (HCC) in
worldwide is on the rise. According to global statistics,
approximately 7 million of people die each year from
liver cancer which includes HCC [1]. The selection of
HCC treatment depends on the tumor heterogeneity,
biological behavior, and liver function [2]. Chemotherapy
is one of the main methods for the treatment of HCC
because it can completely destroy cancer cells. However,
chemotherapy may cause severe simultaneous side-effects
and often lead to multidrug resistance [3]. Therefore,* Correspondence: dzj0911@126.com; wangxijing@21cn.com; wwy0413@126.
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reproduction in any medium, provided the ornovel anti-cancer pharmaceutical products must be devel-
oped; these products may be obtained from Chinese
herbal medicines [4,5]. Several herbs have been found to
have anti-tumor activity and become the main sources of
anti-cancer drugs [6].
Angiogenesis is the formation of new blood vessels
from existing vasculature. This process has been associ-
ated with the growth and dissemination of solid tumors
[7]. The complex process of tumor angiogenesis is associ-
ated with basal membrane injury, endothelial cell prolifer-
ation, cell migration, and the activation of angiogenic
factors, among others [8]. The expressions of several cyto-
kines, such the vascular endothelial growth factor (VEGF)
and angiopoietin (Ang), is involved in this formation
process [9-11]. Cytokines are important regulators of
angiogenesis [12]. Therefore, natural herbs have been con-
sidered as potential novel sources of compounds to inhibit
vascular [13].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in traditional Chinese medicine, which is widely distrib-
uted in certain areas of China and Korea. S. barbata has
known anti-inflammatory and anti-tumor effects. Thus,
this herb has been clinically used for treating inflamma-
tory diseases and cancer. The crude extracts of S. barbata
have demonstrated inhibitory effects on numerous human
cancers in vitro, including hepatoma, colon cancer, lung
cancer, and breast cancer [14-18]. Our previous study con-
firmed that the extract of S. barbata is a potent inhibitor
in hepatoma in vitro and in vivo [19]. To date, several
flavonoids, alkaloids, polysaccharides, and steroids from S.
barbata have been characterized [20-24]. In the present
study, we investigated the anti-angiogenic effects of total
flavonoids of S. barbata (TF-SB) in human umbilical vein




Fetal bovine serum (Gibco BRL, Rockville, MD, USA);
DMEM medium (Gibco, USA); 3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyl tetrazolium bromide (MTT) was pur-
chased from Sigma-Aldrich (St. Louis, MO,USA); Matrigel
(BD Biosciences, San Jose, CA, USA); human VEGF
ELISA kit was purchased from WuHan Boshide Biotech-
nology Co, Ltd. (WuHan, China).
Preparation of TF-SB from Scutellaria barbata D. Don
Dried plant materials of S. barbata were purchased from
Yi Shan Tang Chinese Herbal medicine store (Xi’an,
China) and authenticated according to the descriptions
found in the Chinese Pharmacopoeia. The original herb
was identified as Scutellaria barbata D. Don (SB) by
Run-Xia Liu at Medical School of Xi’an Jiaotong University
(Xi’an, China). The voucher samples, ZLK-ZY-05 (S.
barbata) was deposited at the department of oncology,
the Second Affiliated Hospital of Xi’an Jiaotong
University.
The material was coarsely ground before extraction. A
total of 300 g of the material was extracted twice with
95% ethanol for 3 h in 50°C. The infusion was filtered
through a 1-mm pore-size filter. The leftover on the fil-
ter was collected after evaporated. The crude extract
was isolated by AB-8 macroporous adsorption resin
column in which 70% aqueous ethanol was used to elute
flavonoids. After treatment with AB-8 resin, the flavo-
noids purity increased with a recovery of 69%. The total
flavonoids were stored at 4°C for use.
Cell line and cell culture
MHCC97-H cells and HUVECs were purchased from the
Liver Cancer Institute of Fudan University (Shanghai,
China). The cells were grown in DMEM maximal mediumcontaining 10% inactived fetal bovine serum. Both cell
lines were cultured at 37°C in 5% CO2 under humidified
environment.
MTT assay for the cell viability of HUVEC cells
Viability of HUVECs was assessed by the MTT assay.
Cells were seeded into 96-well plates at the density of
1 × 104 cells/well. After 12 h, the cells were treated with
TF-SB in different concentrations (0, 20, 40, 80 and
160 μg/mL) for 48 h or 72 h, respectively. MTT were
applied to each well after treatment. The supernatant
were removed after 4 h incubation. Subsequently,
DMSO were added to each. The supernatants were re-
moved carefully and 150 μL of dimethyl sulfoxide
(DMSO) were added to each well. The absorbance was
measured at 490 nm through an Enzyme-labeling instru-
ment (ELX800, Bio-Tek, Winooski, VT, USA). This assay
was performed in triplicate. The results represented the
average value of aborbance from three independent
experiments done over multiple days.
In vitro scratch assay
We used the in vitro scratch assay to assess the activity
of TF-SB on migration of HUVECs [25]. HUVECs were
seeded in 12-well plates (2 × 105/well) with complete
medium overnight to obtain a full confluent monolayer.
After 24 h, the cells were scraped away vertically 24 h
later by pipette tip. Each well was washed twice with
PBS to remove debris, and then further incubated for
24 h in serum-free DMEM medium with different
concentrations of TF-SB (0, 40, 80 and 120 μg/mL). The
distances between the 2 edges of the scratch were
photographed on each well using inverted microscope at
a magnification of 100× and analyzed quantitatively.
Tube formation assay
The ability of HUVECs forming network structures was
tested by tube formation assay. As previously described
[26], 96-well plates were plated with 50 μL matrigel and
allowed to polymerize at 37°C for 30 min. HUVECs were
subsequently seeded on the matrigel followed by
addition of different concentrations of TF-SB (0, 40, 80
and 120 μg/mL) and incubation for 9 h at 37°C. The
tube-like structures were photographed on each well
using a phase-contrast microscope (Olympus, Tokyo,
Japan) at a magnification of 100 ×. To quantify the re-
sults, we counted the number of branch points, in which
at least 3 tubes joined.
Chick chorioallantoic membrane (CAM) assay
The CAM assay was performed as previously described
[25]. 60 fertilized chicken eggs (14 ± 2 d) were purchased
from Huxian chicken farm (Xi’an, China). The animals
were housed and handled in strict accordance with the
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of Animal Use and Protection. The protocol was approved
by the Committee on the Ethics of Animal Experiments of
Xi’an Jiaotong University College of Medicine (Certificate
No. 22–9601018). All efforts were made to minimize
animals’ suffering and to keep the numbers of animals
used to a minimum.
Briefly, the eggs were incubated at 37°C in 40–60%
humidity for 96 h. And then, the eggs were randomly
divided into four groups that were treated with different
concentrations of TF-SB. After 7 days, a window (1 ×
1.5 cm2) was opened in the shell to expose a part of the
CAM. Different concentrations of TF-SB samples in
20 μL PBS was loaded onto sterilized gelatin sponges
(2 mm2) that was then applied to the CAM. After 48 h
of incubation, the neovascular numbers in the CAM
around the sponges were photographed with an anatom-
ical microscope (YZ20T4 type). The CAM of the sponge
around were observed after hematoxylin and eosin (HE)
staining [26]. The relationship between leukocyte infil-
tration and angiogenesis were analyzed quantitatively.
Measurement of VEGF levels by ELISA
We used ELISA assay to measure the variation of VEGF
levels in MHCC97H cells and HUVECs. The super-
natant was collected from different treatment groups.
The VEGF level in MHCC97-H cells and HUVECs were
measured by ELISA kit (Boshide) according to the man-
ufacturer’s instructions. The each well was plated with
0.1 mL diluted samples in samples buffer and incubated
90 min at 37°C. Next, 100 μL anti-human VEGF anti-
body was added and incubated for another 60 min. After
washing with PBS for three times, 90 μL TMB color
liquid was added in the dark for 30 min. And then, the
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Figure 1 HPLC analysis of TF-SB. There was a main peak in HPLC, which
flavonoids in TF-SB which were identified as apigenin (B), baicalein (C), luteSolution was applied. All measurements were performed
for three times. The data represented average of absorb-
ance value from three independent experiments.
Statistical analysis
Data were presented as Mean ± standard deviation (SD).
Statistical analysis of the data were performed with
Student’s t-test,one-way analysis of variance (ANOVA)
test and linear regression analysis using the Statistical
Package for Social Sciences version 13.0 (SPSS Inc,
Chicago, IL). p value < 0.05 was considered statistically
significant.
Results
Identification of TF-SB by high performance liquid
chromatography (HPLC)
The components of TF-SB were identified using HPLC.
As shown in Figure 1, the main peak was identified as
scutellarin (A). Other identified flavonoids in TF-SB
included apigenin (B), baicalein (C), luteolin (D). The
contents of flavonoids A-D were 67.2%, 8.7%, 4.6% and
4.3%, respectively.
Effects of TF-SB on the cell viability of HUVECs
The MTT assays showed that the cell viabilities of the
TF-SB treated groups (20, 40, 80 and 160 μg/mL) were
suppressed by 24.3% ± 0.1%, 30.9% ± 1.5%, 55.4% ± 0.9%
and 73.2% ± 0.6% respectively, after 48 h treatment
(Figure 2). The inhibition rate in the TF-SB treated
groups was further decreased after treatment for 72 h,
while the inhibitory rate of the 160 μg/mL group
reached 78.1% ± 0.6%. Therefore, the anti-proliferative
effects of TF-SB on HUVECs occured in a time- and
dose-dependent manner.min0 40 50
C D
was identified as scutellarin (A). There were also some other

































Figure 2 Growth inhibiting effects of TF-SB on HUVECs. Cell viability was determined by MTT method and treated with different
concentrations drug for 48 or 72 h. This assay was performed in triplicate (p < 0.05, ANOVA analysis). *p < 0.05, **p < 0.01 versus the control group.
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Endothelial cell migration is a necessary step of angio-
genesis [9]. In the present study, the effects of TF-SB on
HUVECs migration were determined using the scratch
assay. As shown in Figure 3, cell migration in TF-SB
groups was inhibited in various degrees after 48 h of
treatment. The maximum inhibition was achieved by the
group that received 120 μg/mL TF-SB, which was higher
than control group (p < 0.05) or those with 40 μg/mL
treatment (p < 0.05). The cell migration of HUVECs was
inhibited in a dose-dependent manner by treatment with
TF-SB for 48 h.
TF-SB inhibits HUVEC neovascularization
The formation of tube-like structures is an essential step
in angiogenesis. This process involves matrix degrad-
ation, rearrangement and apoptosis of endothelial cells
[27]. Therefore, HUVECs angiogenesis was observed
using the tube formation assay. As shown in Figure 4,
the capillary tube structures were observed in the basal
membrane of the control group after HUVECs were
placed in the wells. By contrast, the TF-SB treatment sig-
nificantly reduced the formation of tube-like structures
in a dose-dependent manner. Only a few tube-like struc-
tures were formed in the 120 μg/mL TF-SB treated
group.
Effect of TF-SB on angiogenesis in vivo
The chicken chorioallantoic membrane (CAM) assay has
been widely used for developmental and post-
developmental studies of angiogenesis because of the
easy access to the vascularized CAM [28,29]. Moreover,animal experimentation licenses are not compulsory for
chicken embryo experiments in many countries. Further-
more, the CAM assay is rapid, inexpensive, and suitable
for the large-scale screening of potential angiogenesis
regulators [30].
In this study, we used a CAM model to confirm the
effect of TF-SB on angiogenesis in vivo. After treatment
for 48 h, the blood vessel structures were observed using
an anatomical microscope. As shown in Figure 5, a
normal vascular pattern with numerous branching was
observed in the control group. The total number of
blood vessels in the TF-SB treatment was significantly
decreased, as compared with the control group (p < 0.05).
The results indicated that TF-SB could suppress angio-
genesis in vivo.
Relationship between the leukocyte infiltration count and
blood vessel formation
The infiltration of macrophages, lymphocytes, and mast
cells often presented in tumors microenvironment be-
cause these cells may contribute to tumor progression.
Previous studies have suggested that these inflammatory
cells promote the neoplastic progression by stimulating
tumor revascularization and other processes related to
tumor angiogenesis [31]. In the present study, the
leukocyte infiltration count for the surrounding sponge
angiogenesis was observed on the CAM by hematoxylin
and eosin (HE) staining. As shown in Figure 6, leukocyte
infiltration was not correlated with the formation of
large blood vessels. However, the infiltration was po-































Figure 3 Effects of TF-SB on the cell migration of HUVECs. Cell migration was analyzed by the scratch assay. HUVECs were treated with
various concentrations of TF-SB (40, 80 and 120 μg/mL) for 48 h. A: blank control group; B: 40 μg/mL TF-SB group; C: 80 μg/mL TF-SB group;
D: 120 μg/mL TF-SB group. The images were captured under a phase-contrast microscope at a magnification of 100×. Values represent mean ±
SD from three independent experiments. *p < 0.05, **p < 0.01 versus the control group.
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MHCC97-H cells and HUVECs
VEGF is a potent mitogen responsible for the induction
of angiogenesis [32]. The humanized monoclonal anti-
body of VEGF, named bevacizumab, has been used to
treating several cancers [33]. In this study, variations of
the VEGF levels were measured using ELISA. The cells
were treated with different concentrations of TF-SB for
24 or 48 h. The VEGF was then detected in the super-
natant culture media. As shown in Figure 7, VEGF
expression levels were clearlyly decreased after TF-SB
treatment in MHCC97-H cells and HUVECs. Further-
more, the results showed that the VEGF expressionlevels were correlated with the various concentrations of
TF-SB (p < 0.05).
Discussion
Novel treatments, such as targeted therapy and gene
therapy have become an important means of compre-
hensive cancer treatment for various tumors. However,
these therapies have not been widely used because of
their limited efficiency and high cost. Traditional Chinese
medicine has been used in anti-tumor treatment for
thousands of years. These medicines have been used to
enhance immune function, and reduce side effects, as


























Figure 4 The effect of TF-SB on HUVEC tube formation. HUVECs were seeded on Matrigel-coated 96-well plates and incubated in the diluted
medium containing different concentrations of TF-SB for 9 h at 37°C. A: blank control group; B: 40 μg/mL TF-SB group; C: 80 μg/mL TF-SB group;
D: 120 μg/mL TF-SB group. The images were captured under a phase-contrast microscope at a magnification of 100 × and observed the network-
like structures. Values represent mean ± SD from three independent experiments. *p < 0.05, **p < 0.01 compared with the control group.
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tracts from Chinese herbs have been reported in vitro. For
example, BZL101 is an aqueous extract of S. barbata with
anticancer properties against several human cancers [34].
The crude extract of S. barbata similarly has anticancer
and anti-angiogenic activity in vitro and in vivo [19,35].
S. barbata is one of the conventional anticancer drugs
in China because of its significant anti-tumor activity
and inhibition of angiogenesis [36]. S. barbata is effectiveagainst a wide range of tumors. The extracts of S. barbata
greatly could greatly inhibit the cell growth in lung cancer,
leukemia, colon cancer, hepatoma, and skin cancer
[15-18]. Lee et al. reported that S. barbata decreased
the proliferation of myometrial and leiomyomal cells
originally promoted by HCG [37]. The chemical com-
position of S. barbata includes flavonoids, diterpenoids,
and polysaccharides. Flavonoids are considered the































Figure 5 The effects of TF-SB on the angiogenesis of CAM. The chick chorioallantoic membrane of 7-day-old chick embryos were treated
with various concentrations of TF-SB and incubated for 48 h. A: blank control group; B: 40 μg/mL TF-SB group; C: 80 μg/mL TF-SB group;
D: 120 μg/mL TF-SB group. The angiogenesis around the gelatin sponges was photographed with an anatomical microscope. Values represent
mean ± SD from fifteen eggs. *p < 0.05, **p < 0.01 compared with the control group.
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the proliferation, migration and tube formation of endo-
thelial cells. Our results showed that TF-SB inhibited the
proliferation and migration of HUVECs in a dose-
dependent manner. Thus, TF-SB could significantly sup-
press the progress of angiogenesis in HUVECs.
Tumor neovascularization is defined as the process of
new blood vessel formation in solid neoplasms [27]. Theactivation of angiogenic pathways is required for tumor
spreading, and the proliferation of metastatic cells in
distant organs [38]. In a phase IB, multicenter clinical
trial of the drug Bezielle in the USA, an aqueous extract
of S. barbata, was safely administered to the patients
and demonstrated promising clinical evidence of anti-
cancer activity in a heavily pretreated population of
women with metastatic breast cancer [39]. The ethanol
Figure 6 The relationship between leukocyte infiltration count and formation of blood vessels. The leukocyte infiltration and blood
vessels on the CAM were observed under the microscope by HE staining. and no correlation between the formations of big blood vessels. A: The
leukocyte infiltration was positively correlated with small blood vessels (r = 0.883, p < 0.05); B: The leukocyte infiltration had no correlation with





























































Figure 7 Effect of TF-SB on the expression of VEGF in both
MHCC97-H cells and HUVECs. Cells were treated with different
concentrations of TF-SB for 24 h or 48 h. The protein secretion levels
of VEGF were examined by ELISA in MHCC97-H cells (A) and HUVECs
(B). The VEGF expression in the two cell lines were significantly
reduced. This assay was performed in triplicate. *p < 0.05 versus the
control group.
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colorectal cancer mouse xenograft model by suppressing
the SHH pathway [40]. In the present study, angiogenesis
of HUVECs was observed through tube formation assay.
We found that TF-SB could significantly suppress the
process of angiogenesis of HUVECs.
Inflammation, cytokine activation, and angiogenesis
are common features of the tumor microenvironment
during the progression of malignancy [41]. These bio-
logical processes often share mutual pathways related to
cancer progression [42]. Inflammatory cells are macro-
phages or monocytes induced by various cytokines to
become tumor-associated macrophages (TAM) during
tumorigenesis. These cells are considered contributing
factors for creating the required microenvironment for
angiogenesis [43]. In the present study, we found that
TF-SB inhibited the angiogenesis of CAM in vivo. Simul-
taneously, the surrounding sponge layer had numerous
infiltrating inflammatory cells by HE staining. A positive
correlation was found between leukocyte infiltration and
the abundance of small blood vessels.
VEGF may be combined with specific endothelial cell
receptors, which are secreted by the autocrine and para-
crine pathways to promote angiogenesis [44]. In the present
study, the results showed that TF-SB downregulated the
expression of VEGF in the MHCC97-H cells and HUVECs.
Conclusion
In conclusion, TF-SB treatment could significantly sup-
press the process of angiogenesis in HUVECs grown on
matrigels in vitro, and the angiogenesis of CAM in vivo.
However, TF-SB is composed of several compounds,
including scutellarin, apigenin, baicalein and luteolin,
among others. The anticancer effects of these individual
components or of various combined ingredients remain
unknown. Further experimental studies are required to
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